Unassociated Document
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2013

 
Commission File Number: 001-11960

 
AstraZeneca PLC
 
 
2 Kingdom Street, London W2 6BD
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X      Form 40-F __
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______           
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
Yes __     No X
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 


 
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
 
On 30 March 2013, the interest of Dr Briggs Morrison, a person discharging managerial responsibilities, in the American Depositary Shares (ADSs) of AstraZeneca PLC changed as detailed below.  One ADS equals one Ordinary Share.
 
The change in interest relates to the vesting of an award of 24,723 shares made in March 2012 under the AstraZeneca Restricted Share Plan. In accordance with the terms of the award, Dr Morrison has become beneficially entitled to these shares.
 
Following certain tax deductions, Dr Morrison has received 14,339 shares into a personal brokerage account.
 
For tax purposes, the fair market value of the shares at vest was $49.98 pence per share being the closing price of AstraZeneca ordinary shares on the last trading day preceding the vesting day.
 
 
A C N Kemp
Company Secretary
3 April 2013
 
 

  
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 03 April 2013
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary